Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
14 Julho 2023 - 9:00AM
Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema (HAE) and focused on life-changing therapies for rare
and niche allergic and immunological diseases, today announced that
it will present information regarding patient preference for
efficacy measures when starting on or switching to a new
preventative therapy at the upcoming 2023 US Hereditary Angioedema
Association (HAEA) National Summit in Orlando, Florida from July
20-23, 2023.
Sarah Friedhoff, Director of Patient Advocacy at Astria
Therapeutics, will present “People Living with Hereditary
Angioedema (HAE) Prioritize Attack-Free Status as a Target for
Therapeutic Efficacy,” in a poster session beginning on Friday,
July 21, at 7:45am ET.
This poster will be available in-person to registered attendees
and will be made available on www.astriatx.com following the
conference.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by rare and niche allergic and immunological
diseases. Our lead program, STAR-0215, is a monoclonal antibody
inhibitor of plasma kallikrein in clinical development for the
treatment of hereditary angioedema. Learn more about our company on
our website, www.astriatx.com, or follow us on Twitter and
Instagram @AstriaTx and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230714824985/en/
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024